About Alpha-2,8-sialyltransferase 8F
Alpha-2,8-sialyltransferase 8F (ST8SIA6) is a protein
from Homo sapiens identified by UniProt accession
P61647, 398 residues long.
MolForge cross-references it against 0 known binders and
59 disease associations.
Target properties
| Protein name | Alpha-2,8-sialyltransferase 8F |
| UniProt accession | P61647 |
| Gene | ST8SIA6 |
| Organism | Homo sapiens |
| Length | 398 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (59)
Diseases linked to this target (Open Targets).
- sleep apnea measurement · score 0.33
- emotional symptom measurement · score 0.33
- pancreatic adenocarcinoma · score 0.21
- Age-related cataract · score 0.14
- prostate cancer · score 0.11
- Familial prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- hepatocellular carcinoma · score 0.10
- aspartate aminotransferase to alanine aminotransferase ratio · score 0.10
- lung adenocarcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P61647-F1 | alphafold | PREDICTED | 85.56 | — |
Amino-acid sequence (398 residues)
MRPGGALLAL LASLLLLLLL RLLWCPADAP GRARILVEES REATHGTPAA LRTLRSPATA VPRATNSTYL NEKSLQLTEK CKNLQYGIES FSNKTKGYSE NDYLQIITDI QSCPWKRQAE EYANFRAKLA SCCDAVQNFV VSQNNTPVGT NMSYEVESKK EIPIKKNIFH MFPVSQPFVD YPYNQCAVVG NGGILNKSLC GTEIDKSDFV FRCNLPPTTG DVSKDVGSKT NLVTINPSII TLKYGNLKEK KALFLEDIAT YGDAFFLLPA FSFRANTGTS FKVYYTLEES KARQKVLFFH PKYLKDLALF WRTKGVTAYR LSTGLMITSV AVELCKNVKL YGFWPFSKTV EDIPVSHHYY DNKLPKHGFH QMPKEYSQIL QLHMKGILKL QFSKCEVA
Explore Alpha-2,8-sialyltransferase 8F with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets